Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$86.97 USD
-0.61 (-0.70%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $86.92 -0.05 (-0.06%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
BPMC 86.97 -0.61(-0.70%)
Will BPMC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPMC
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up
Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up
Other News for BPMC
Blueprint Medicines (BPMC) Receives a Hold from Barclays
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In
Blueprint Medicines to Present at Upcoming Investor Conferences
BPMC Crosses Below Key Moving Average Level